Please login to your online account to display your discounted pricing

Promega™ Riboprobe™ Combination Systems

For in vitro prepartion of high specific activity single-stranded RNA probes or microgram quantities of defined RNA transcripts from cloned DNA inserts

$364.87 - $364.87

Specifications

For Use With (Application) Generation of high-specific-activity RNA probes, generation of microgram quantities of RNA transcripts, generation of RNA processing substrates, generation of antisense RNA
Storage Requirements Store at -20°C.
View More Specs
Includes:  RNA polymerase(s); pGEM™ Express Positive Control Template; RQ1 RNase-free DNase; Recombinant RNasin™ Ribonuclease Inhibitor; rATP; rCTP; rGTP; rUTP; DTT; Transcription-optimized buffer, 5X; Nuclease-free water
Products
Catalog Number Mfr. No. Includes Price Quantity    

PR-P1450

 
promega™
P1450
500U T3 RNA Polymerase, 500U T7 RNA Polymerase, 5μg pGEM™ express positive control template, 500μL transcription optimized 5X Buffer, 2500U recombinant RNasin™ R Each for $364.87

PR-P1460

 
promega™
P1460
500U SP6 RNA Polymerase, 500U T7 RNA Polymerase, 5μg pGEM™ express positive control template, 500μL transcription optimized 5X Buffer, 2500U recombinant RNasin™ R Each for $364.87
Description & Specifications

Specifications

For Use With (Application) Generation of high-specific-activity RNA probes, generation of microgram quantities of RNA transcripts, generation of RNA processing substrates, generation of antisense RNA
Storage Requirements Store at -20°C.

  • All required reagents (excluding radioisotope) for performing transcription reactions in vitro and DNase to remove the template following transcription are included
  • SP6, T7 and T3 RNA Polymerases are extremely promoter-specific, allowing production of virtually homogeneous RNA using plasmid DNA as a template
  • Combination systems allow synthesis of RNA corresponding to either the coding or noncoding strand of cloned DNA from a single plasmid construct

U.S. Patent 5,552,302; Australian Patent 646803 and other patents.
Australian Patents 616881 and 641261 and other pending and issued patents, which claim vectors encoding a portion of human placental ribonuclease inhibitor, are exclusively licensed to Promega Corporation.